Pfizer Inc. $PFE Shares Sold by Invst LLC

Key Points

• Invst LLC reduced its stake in Pfizer Inc. by 83.0%, selling 45,340 shares and now owning 9,315 shares worth $236,000.
• Recent analyst reports have led to varied price target adjustments for Pfizer, with a consensus target price of $28.12 and a current rating of "Hold."
• Pfizer announced a quarterly dividend of $0.43, yielding 7.2%, with a payout ratio of 91.49% as of the last ex-dividend date.

Invst LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 83.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,315 shares of the biopharmaceutical company's stock after selling 45,340 shares during the period. Invst LLC's holdings in Pfizer were worth $236,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. William B. Walkup & Associates Inc. boosted its stake in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after purchasing an additional 454 shares during the period. Members Trust Co increased its holdings in Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 467 shares during the period. Sutton Place Investors LLC grew its stake in shares of Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares during the period. MSH Capital Advisors LLC grew its stake in Pfizer by 1.4% in the 1st quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock valued at $876,000 after acquiring an additional 485 shares during the period. Finally, Signature Estate & Investment Advisors LLC lifted its holdings in Pfizer by 2.6% in the 1st quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company's stock valued at $488,000 after purchasing an additional 486 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 3.8%

PFE stock traded down $0.95 during trading on Friday, hitting $23.91. 81,158,118 shares of the company's stock were exchanged, compared to its average volume of 34,996,196. The business has a 50-day moving average price of $24.79 and a two-hundred day moving average price of $24.28. The stock has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the business earned $0.60 earnings per share. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

Several research firms have recently commented on PFE. HSBC reduced their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Finally, Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.